Other investigational anti-fibrotic agents, such as FGF21 and metformin, display improvement in hepatic steatosis and a decrease in hepatic stiffness by an increase of insulin-sensitization and normalization of serum aminotransferases, respectively. The gene discussed is FGF21; the disease is Hepatic steatosis.